Physician profile
Igor Galan
NPI 1114313087
$16,215.79
in general payments reported to CMS, 2019-2025
35 companies · $4,853 in 2025
The $4,853 reported for 2025 was more than what 87% of Pain Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $405).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $318 · 2020: $867 · 2021: $2,264 · 2022: $4,705 · 2023: $2,897 · 2024: $310 · 2025: $4,853.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,029 · Honoraria: $2,200 · Travel and Lodging: $1,569 · Education: $263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,028.59 |
| Honoraria | $2,200.00 |
| Travel and Lodging | $1,568.73 |
| Education | $263.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $4,907.38 | 2020-2025 | Xcopri |
| Abbott Laboratories | $3,955.52 | 2019-2025 | Proclaim, Eterna, Octrode |
| Teva Pharmaceuticals USA, INC. | $1,427.00 | 2021-2025 | Austedo Xr, Austedo |
| Abbvie INC. | $1,373.68 | 2021-2025 | |
| Amgen INC. | $557.08 | 2019-2023 | Aimovig |
| Medtronic, INC. | $399.70 | 2022-2023 | Synchromedii |
| Kyowa Kirin, INC. | $320.04 | 2022-2023 | Nourianz |
| Sunovion Pharmaceuticals INC. | $307.74 | 2021-2022 | |
| Biotronik Nro, INC. | $279.39 | 2025 | Prospera |
| Allergan, INC. | $273.05 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $214.37 | 2019-2023 | |
| Neurocrine Biosciences, INC. | $209.55 | 2022-2023 | Ongentys, Ingrezza |
| Biohaven Pharmaceutical Holding Company Ltd. | $206.44 | 2022 | |
| Ucb, INC. | $202.08 | 2022-2023 | Briviact |
| Lilly USA, LLC | $173.73 | 2019-2023 | Emgality, Reyvow |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $172.72 | 2023 | Neuwave |
| Nevro Corp. | $135.71 | 2021 | |
| Tanabe Pharma America, INC. | $132.57 | 2022-2023 | |
| Almatica Pharma LLC | $108.62 | 2022-2023 | Gralise |
| Sumitomo Pharma America, INC. | $105.80 | 2023 | Aptiom |
| Nalu Medical, INC. | $102.14 | 2024 | Nalu Neurostimulation System |
| Supernus Pharmaceuticals, INC. | $88.61 | 2020-2021 | |
| Amneal Pharmaceuticals LLC | $88.11 | 2022-2025 | Rytary, Lyvispah, Crexont |
| Eisai INC. | $84.02 | 2021-2023 | |
| Tersera Therapeutics LLC | $70.19 | 2024 | Prialt |
| Biohaven Pharmaceuticals, INC. | $60.71 | 2021 | |
| Scilex Pharmaceuticals INC. | $45.17 | 2019-2023 | Ztlido |
| Fidia Pharma USA INC. | $40.33 | 2022 | |
| Impel Pharmaceuticals INC. | $33.66 | 2022-2023 | Trudhesa |
| Pfizer INC. | $30.86 | 2023 | |
| Genentech USA, INC. | $25.80 | 2023 | Ocrevus |
| Biodelivery Sciences International, INC. | $25.73 | 2019-2020 | |
| Catalyst Pharmaceuticals, INC. | $24.06 | 2023 | Fycompa |
| Biogen, INC. | $19.81 | 2021 | |
| Neurelis, INC. | $14.42 | 2024 | Valtoco |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Igor Galan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.